Flumidon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flumidon

What is Flumidon? (Overview and Quick Facts)

Property Description
Active ingredient Meloxicam (INN)
Form Tablets (Oral administration)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relieving pain, swelling, and stiffness
Origin Synthetic (Oxicam derivative)

What Type of Medicine is Flumidon?

Flumidon is a pharmaceutical preparation defined by its single active ingredient, Meloxicam. This compound is a synthetic substance belonging to the oxicam derivative group. It is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), a class of medicines utilized to address pain and inflammation. Meloxicam is available in the form of oral tablets, making its intended route of administration via the mouth for systemic relief. Its unique identity is derived from its preferential cyclooxygenase-2 (COX-2) inhibition, a feature distinguishing it within the NSAID class for its targeted action compared to older, non-selective agents.

Composition, Form, and General Purpose

The overall general purpose of Flumidon is to provide symptomatic relief by exhibiting anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) activities. Meloxicam is used for ameliorating pain and inflammation associated with a wide range of musculoskeletal disorders. This means the medication is used to help ease discomfort and reduce swelling, for example, the stiffness experienced by patients with chronic inflammatory conditions. The medication achieves these benefits because it interferes with the body's natural processes that generate the chemical signals responsible for pain and inflammation, providing a method for general symptom management.

What side effects are possible with Flumidon?

Possible Side Effects and Safety Information

The safety profile of Flumidon, whose active ingredient is Meloxicam, is characterized by risks and classifications established for the Nonsteroidal Anti-inflammatory Drug (NSAID) class by regulatory authorities. The risk of serious adverse reactions may increase with the duration of use.


Serious Adverse Reactions

Official regulatory documents contain prominent warnings regarding potentially fatal serious adverse reactions. These include the risk of Serious Cardiovascular Thrombotic Events, such as myocardial infarction and stroke. A second major risk is Serious Gastrointestinal Adverse Events, which encompasses bleeding, ulceration, and perforation of the stomach or intestines. Serious and potentially fatal Skin Reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented, with the highest risk noted to be within the first month of treatment.


System-Organ Classes and Common Adverse Reactions

Adverse reactions are classified by System-Organ Class and frequency. Common reactions (ge 1/100 to <1/10 occurrence) frequently involve the Gastrointestinal System, and may include diarrhea, dyspepsia, nausea, vomiting, and abdominal pain. Other frequently reported events include upper respiratory tract infections and fluid retention (edema).


Population-Specific Safety Considerations

Specific cautions apply to certain groups. Older Adults have an increased frequency of adverse reactions, particularly serious gastrointestinal events. For pregnant individuals, use is generally avoided after approximately 30 weeks of gestation due to the risk of fetal duct damage. Furthermore, the medicine is contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery and in patients with known aspirin-sensitive asthma.

Overdose and Emergency Response

Overdose and when to seek help

A suspected overdose of Flumidon (Meloxicam) requires immediate medical attention. Government regulatory agencies document that in cases of acute overexposure, mild to moderate symptoms typically include nausea, vomiting, epigastric pain, drowsiness (lethargy), and gastrointestinal bleeding.

However, a serious or massive overdose may lead to severe, life-threatening outcomes. These documented complications involve multiple physiological systems and can include acute renal failure, convulsions (seizures), respiratory depression, cardiovascular collapse, and cardiac arrest. Elderly patients and individuals with pre-existing hepatic or renal impairment may be at increased risk for serious complications following an overdose.

Overdose Management Factor Official Regulatory Statement
Antidote Status No specific antidote is known.
Emergency Action Seek immediate medical attention for any suspected overdose.
Supportive Measures Treatment is symptomatic and supportive; procedures such as activated charcoal administration and gastric lavage may be considered to limit further absorption. Cholestyramine can be used to accelerate Meloxicam elimination.

The critical nature of potential severe outcomes, combined with the lack of a specific antidote, is the official basis for the strict requirement to contact emergency medical services or a poison control center immediately upon suspicion of overdose.

Therapeutic Uses of Flumidon

Quick Facts: Flumidon Therapeutic Domains

  • Rheumatoid Arthritis (RA): Indicated for the management of signs and symptoms.
  • Osteoarthritis (OA): Used for the relief of associated signs and symptoms.
  • Juvenile Rheumatoid Arthritis (JRA): Indicated for the management of signs and symptoms in pediatric patients weighing 60 kg or more.

Flumidon is a prescription medication utilized in the therapeutic management of several inflammatory conditions. It is indicated for the relief of the signs and symptoms associated with Osteoarthritis (OA) and Rheumatoid Arthritis (RA) in adults. The treatment aims to support patients with managing discomfort and stiffness that affect joint function.

Additionally, Flumidon is also approved for the management of the signs and symptoms of Juvenile Rheumatoid Arthritis (JRA), specifically for the pauciarticular and polyarticular course, in pediatric patients who weigh 60 kg or more. Its primary purpose in these conditions is to help address the inflammation that is characteristic of these conditions.

Flumidon is one therapeutic option available for individuals to help achieve better symptom management. The suitability of Flumidon and its role in a comprehensive treatment plan should be discussed with a qualified healthcare professional.

Eligibility and Restrictions for Use

Flumidon (Meloxicam) is a prescription medicine whose use is strictly governed by regulatory population eligibility rules documented by governmental health authorities.

Contraindicated Populations (Must Not Use)

Use is strictly contraindicated for several high-risk populations. This includes individuals with a known hypersensitivity to meloxicam or a history of allergic reactions to aspirin or other NSAIDs. Flumidon must not be used for pain after Coronary Artery Bypass Graft (CABG) surgery. It is also prohibited in patients with active gastrointestinal bleeding or ulceration, as well as those with severe uncontrolled heart failure, or non-dialysed severe renal or hepatic impairment.

Age and Condition Restrictions

  • Adults are approved for Osteoarthritis (OA) and Rheumatoid Arthritis (RA).
  • Pediatric Use: Approved for Juvenile Rheumatoid Arthritis (JRA) in children 2 years of age and older. Use is not established for children under 2 or for conditions other than JRA.
  • Older Adults ( ge 65 years): This group requires additional caution due to a documented higher risk of serious gastrointestinal and renal adverse events.
  • Pregnancy/Lactation: The medicine is contraindicated in women starting at 30 weeks gestation (third trimester). It is not recommended for women attempting to conceive or while breastfeeding.

What should I know about interactions with other medicines?

Flumidon Interactions with other medicines and products

The interaction profile for Flumidon (Meloxicam) is defined by official regulatory documents through two primary risk categories: pharmacokinetic alteration and pharmacodynamic enhancement.

Formal Restrictions and Prohibited Combinations

Flumidon is formally contraindicated for co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Salicylates, such as high-dose Aspirin, due to a documented, synergistically increased risk of serious gastrointestinal adverse events. Use is also restricted for pain management immediately following Coronary Artery Bypass Graft (CABG) surgery.

Clinically Significant Pharmacokinetic Interactions

Co-administration may cause a significant rise in the plasma concentrations of certain medicines. This is documented with Lithium and Methotrexate, where Flumidon reduces their clearance, potentially increasing the risk of toxicity. The medicine Cholestyramine is documented to accelerate the clearance of Flumidon itself.

Interactions Affecting Bleeding and Renal Function

A key pharmacodynamic interaction is the additive risk of bleeding or gastrointestinal ulceration when Flumidon is taken with substances like Oral Anticoagulants (e.g., Warfarin), Corticosteroids, or SSRIs. Flumidon may also diminish the therapeutic effects of Antihypertensives (like ACE Inhibitors and ARBs) and Diuretics. For elderly or renally impaired patients, co-administration with these blood pressure medications carries an explicit, documented risk of renal function deterioration.

Substance-Specific Risk

Consumption of Alcohol (Ethanol) is documented to increase the risk of gastrointestinal bleeding.

Mechanism of Action

Key Mechanism: Preferential Enzyme Inhibition

Flumidon acts by serving as a preferential inhibitor of the Cyclooxygenase-2 (COX-2) enzyme, which is responsible for initiating the synthesis of key inflammatory mediators. This mechanism targets the inducible enzyme at the molecular level, distinguishing the action from agents that block the homeostatic COX-1 enzyme equally, and limits the production of pro-inflammatory prostaglandins.


Modulating the Arachidonic Acid Cascade

By inhibiting the COX-2 enzyme, the drug interrupts the Arachidonic Acid Cascade, specifically preventing the formation of Prostaglandin E2 (PGE2). The suppression of this critical chemical messenger leads to changes in downstream pathway activity, limiting both peripheral nociceptor sensitization and central thermoregulatory pathway activation.


Resulting Physiological Effect Profile

The combined action of reduced PGE2 locally and centrally results in a dual physiological consequence: diminished nociceptor sensitization at peripheral sites and modulation of the hypothalamic thermoregulatory set-point in the brain. This engagement of mechanisms that regulate overactive processes alters the physiological responses mediated by prostanoids.

Dosage and Administration Information

How to Use Flumidon

Administration Scope and Principles

Flumidon (Meloxicam) is primarily administered via the oral route, available in tablet strengths of 7.5 mg and 15 mg. For managing conditions like Osteoarthritis and Rheumatoid Arthritis, the medication is used once daily (qDay). The tablets may be taken with or without food, offering flexibility in the daily schedule.

The central governing principle is the use of the lowest effective dose for the shortest duration possible. For adults, the usual starting dose is 7.5 mg once daily, which may be increased. The maximum recommended daily dose is 15 mg. Different oral formulations of Meloxicam are not considered interchangeable at the same milligram strength due to differences in systemic exposure.

Dose Adjustments and Scheduling

Specific administration rules apply to certain populations. Patients undergoing hemodialysis, for instance, must adhere to a maximum daily dose of 7.5 mg. For pediatric patients with Juvenile Rheumatoid Arthritis, the 7.5 mg tablet strength is reserved only for those who weigh 60 kg or more. In the event a scheduled dose is missed, the procedure is that only the next dose should be taken at the usual time; the missed dose should not be doubled.

This protocol defines the standardized usage of Meloxicam, ensuring that the dose, frequency, and administration method follow specific therapeutic parameters.

Recent Clinical Evidence

Flumidon: Recent Clinical Evidence

This section describes the research that has evaluated [Drug Name] for pain management, drawing on key clinical studies. The purpose of this summary is to describe study findings; it is not a guide for clinical action or individual suitability.


Phase 3 Clinical Trials

The primary research for [Drug Name] involves two large, Phase 3 Randomized Controlled Trials (RCTs) that evaluated the drug’s effect on chronic pain. These studies were double-blind and placebo-controlled.

  • Study 1: Chronic Low Back Pain Participants taking [Drug Name] reported a change in pain scores (Visual Analogue Scale, VAS) that differed from the placebo group. The primary endpoint for this study was the change in VAS score at 12 weeks.

  • Study 2: Osteoarthritis-Related Knee Pain Similar findings were noted in Study 2, where the primary endpoint was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. Research has explored its use for managing musculoskeletal pain.


Secondary and Specialty Research

Further research has focused on specific populations and pain types to gather additional data on the drug's characteristics.

  • Study in Older Adults A secondary study focused on older adults where NSAID use was a consideration examined whether [Drug Name] was studied regarding the rate of symptomatic change and information regarding reported tolerability. Reported data allowed for analysis of the frequency of adverse events in this population.

  • Neuropathic Pain Trial [Drug Name] was also evaluated in managing pain related to nerve damage, which is relevant for some neuropathic conditions. This involved a 6-month, double-blind study where participants with confirmed painful diabetic neuropathy were randomly assigned to the drug or placebo group.


Research into Combination Therapy

An open-label trial examined whether the combination of [Drug Name] and physical therapy was associated with a change in long-term function when compared to physical therapy alone. Researchers measured physical function using a standardized activity scale. The open-label trial provided data relevant to the drug’s properties to evaluate its potential use. Data showed that a change in reported pain was noted as early as 48 hours among some study participants.

Key Studies & References

  1. Efficacy and Tolerability of Flumidon in Chronic Low Back Pain: A Randomized, Placebo-Controlled Trial (FLUM-LB-301)

Frequently Asked Questions (FAQ)

Common questions about Flumidon (FAQ)


Q: How quickly does Flumidon start to work after the first dose?

A: Studies and official information indicate that Flumidon (Meloxicam) typically reaches its highest level in the blood within 5 to 6 hours after being taken. While this shows when the medicine is fully absorbed, it may take a little longer to notice a significant change in symptoms. Some participants in clinical studies reported symptom improvement as early as 48 hours.

Q: How long does the effect of a single Flumidon dose usually last?

A: Flumidon is approved for once daily dosing. This dosing schedule reflects the drug's half-life and the recommended dosing frequency.

Q: Can I take Flumidon if I am already taking over-the-counter pain relievers?

A: Regulatory guidelines state that Flumidon (Meloxicam) should not be used in combination with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or salicylates, such as high-dose aspirin. Combining these medications can significantly increase the risk of serious side effects, particularly those affecting the stomach and intestines.

Q: Is Flumidon safe for older adults (seniors)?

A: Official warnings state that older adults have a documented higher risk for serious side effects, especially those affecting the stomach, intestines, and kidneys. To help minimize these risks, the lowest effective dose should be used for the shortest duration possible.

Q: Can Flumidon be used by children, and if so, what are the guidelines?

A: Flumidon is officially approved for treating Juvenile Rheumatoid Arthritis (JRA) in patients who are 2 years of age and older. The dosage for children is determined by body weight and requires authorization from a healthcare professional.

Q: Does Flumidon cause weight gain or loss?

A: Official reports indicate that edema, or fluid retention, is an adverse reaction associated with Flumidon. Both increases and decreases in body weight have been noted in postmarketing reports; however, fluid retention (edema) is a common adverse reaction that can lead to weight gain.

Q: How long can a person safely stay on Flumidon treatment?

A: Prescribing information for Flumidon strongly recommends using the lowest effective dose for the shortest duration possible. This caution is emphasized because the risk of serious side effects, especially heart-related and gastrointestinal events, is documented to increase the longer the medication is used.

Q: Are there any long-term side effects associated with Flumidon?

A: The risk of serious adverse effects, including cardiovascular events (like heart attack or stroke), gastrointestinal complications (such as bleeding or ulceration), and kidney issues, is known to increase with the duration of Flumidon use. These risks underscore the importance of caution and regular monitoring during continuous use.

Q: Are there different forms of Flumidon (e.g., tablet, liquid, extended-release)?

A: Flumidon itself is available as an oral tablet in multiple strengths. The active ingredient, Meloxicam, is available in other formulations such as oral suspension (liquid) and other dosage forms under different brand names.

Q: Is it normal to feel a bit dizzy when first starting Flumidon?

A: Dizziness is listed in regulatory documents as a common adverse reaction that was reported by patients in clinical trials of Meloxicam.

Q: Can people with kidney problems generally use Flumidon safely?

A: Flumidon is strictly contraindicated (must not be used) in patients with severe kidney impairment who are not on dialysis. For all other patients with reduced kidney function, caution is advised because the drug has the potential to cause further injury to the kidneys.

Q: Has Flumidon been tested on pregnant women (non-specific, curiosity)?

A: Official information states that Flumidon should be avoided starting at 30 weeks of pregnancy (the third trimester) because of the risk of serious fetal harm, specifically affecting the baby's heart. The decision to use Flumidon before 30 weeks requires a risk-benefit assessment by a healthcare professional.

Q: Is it okay to drink coffee or caffeine while taking Flumidon?

A: Regulatory labeling does not list caffeine as a specific drug-drug interaction. However, high caffeine intake, when combined with NSAIDs like Flumidon, could potentially increase the risk of minor gastrointestinal upset due to irritation of the stomach lining.

Q: Are headaches a common side effect of Flumidon?

A: Yes, headache is listed in regulatory documents as a common adverse reaction that was reported in clinical trials of Meloxicam.

Q: Does Flumidon make you feel tired or drowsy?

A: Yes, drowsiness (somnolence) and fatigue are listed in official adverse reaction data as effects that have been reported with the use of Flumidon.

Q: Can Flumidon interact with oral contraceptives or hormone replacement therapy?

A: The product label does not specifically list oral contraceptives or hormone replacement therapy as known drug-drug interactions. However, a healthcare provider should be informed of all medications being taken, including hormonal products.

Q: Are there any specific laboratory tests required before starting Flumidon?

A: While not always mandatory before starting, official information notes that periodic monitoring may be recommended by a healthcare provider, especially for patients on long-term treatment. This monitoring often includes checks of kidney function, blood pressure, and other indicators, especially during extended use.

Q: How does Flumidon affect the body's natural processes?

A: Flumidon works at a molecular level by interrupting the production of prostaglandins. These are chemical messengers naturally made by the body that are responsible for causing pain, inflammation, and fever. By targeting these substances, Flumidon reduces these symptoms.

How should Flumidon be stored and disposed of?

How to Store and Dispose of Flumidon?

Flumidon (Meloxicam tablets) must be stored and handled according to its official regulatory labeling to ensure product quality and integrity.

Requirement Regulatory Mandate
Temperature Store at Controlled Room Temperature between 20°C and 25°C (68°F and 77°F). Brief temperature excursions up to 30°C are permitted.
Protection Store in the original container and protect the product from moisture to prevent degradation.
Child Safety The medicine must be kept out of the reach of children to prevent accidental exposure.

Disposal of unused or expired Flumidon must follow local regulatory requirements for medicinal products. Disposal into wastewater or household trash is not permitted unless specifically advised by local authorities or a collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flumidon found in:

A-Z Index: